No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population
- PMID: 28527613
- DOI: 10.1016/j.jogc.2016.12.005
No. 344-Opportunistic Salpingectomy and Other Methods of Risk Reduction for Ovarian/Fallopian Tube/Peritoneal Cancer in the General Population
Abstract
Objective: This guideline reviews the potential benefits of opportunistic salpingectomy to prevent the development of high grade serous cancers (HGSC) of the ovary/fallopian tube/peritoneum based on current evidence supporting the fallopian tube origin of disease.
Intended users: Gynaecologists, obstetricians, family doctors, registered nurses, nurse practitioners, residents, and health care providers.
Target population: Adult women (18 and older): OPTIONS: Women considering hysterectomy who wish to retain their ovaries in situ have traditionally also retained their fallopian tubes. In addition, women undergoing permanent surgical sterilization have usually undergone tubal ligation using various methods rather than undergoing surgical removal of the entire fallopian tube.
Evidence: For the sections "Evidence Supporting the Hypothesis That HGSC Originates in the Fallopian Tube" and "Current Literature on the Effects and Safety of Opportunistic Salpingectomy," relevant studies were searched in PubMed, Medline, and the Cochrane Systematic Reviews using the following terms, either alone or in combination, with the search limited to English language materials: "high grade serous cancers ovary," "fallopian tube," "peritoneum," "opportunistic salpingectomy," "epithelial ovarian cancers," "origin," "tubal carcinoma in situ," "BRCA mutation," "prophylactic salpingectomy," "inflammation," "clear cell," and "endometrioid." The initial search was performed in March 2015 with a final literature search in March 2016. Relevant evidence was selected for inclusion in the following order: meta-analyses, systematic reviews, guidelines, randomized controlled trials, prospective cohort studies, observational studies, non-systematic reviews, case series, and reports. The total number of studies identified was 458, and 56 studies were included in this review. For the section "Other Factors Influencing the Risk of Developing "Ovarian" Cancers" a general Medline search was carried out using the terms "ovarian neoplasm" and "prevention." The search included papers published from December 2005 to March 2016. Meta-analyses were preferentially selected except where no such review was found. Additional searches for each subheading were also conducted (e.g., "ovarian neoplasm" and "tubal ligation.") Additional significant articles were identified through cross-referencing the identified reviews. For the search for "ovarian neoplasm" and "prevention," 10 meta-analyses were identified. For the search for "ovarian neoplasm" and "tubal ligation," an additional 4 meta-analyses were identified.
Validation methods: The content and recommendations were drafted and agreed on by the principal authors. The Executive and Board of the Society of Gynecologic Oncology of Canada reviewed the content and submitted comments for consideration, and the Board of the SOGC approved the final draft for publication. The quality of evidence was rated using the criteria described in the Grading of Recommendations Assessment, Development and Evaluation methodology framework (Table 1). The interpretation of strong and weak recommendations is described in Table 2. The summary of findings is available on request.
Benefits, harms, and/or costs: The addition of opportunistic salpingectomy to a planned hysterectomy or permanent sterilization did not increase rates of hospital readmission (OR 0.91, 95% CI 0.75 to 1.10 and OR 0.8, 95% CI 0.56 to 1.21, respectively) or blood transfusions (OR 0.86, 95% CI 0.67 to 1.10 and OR 0.75, 95% CI 0.32 to 1.73, respectively) but did increase the overall operating time (by 16 minutes and 10 minutes, respectively) in a retrospective review of 43 931 women. The risk of repeat surgery for tubal pathology among women with retained fallopian tubes after hysterectomy was at least doubled (OR 2.13, 95% CI 1.88 to 2.42 in a population-based study of 170 000 women). If general gynaecologists were to consider removal of fallopian tubes at the time of every hysterectomy and sterilization procedure with referral of all patients with HGSC for hereditary cancer counselling and genetic testing, experts project a potential reduction in the rate of HGSC by 40% over the next 20 years.
Guideline update: Evidence will be reviewed 5 years after publication to decide whether all or part of the guideline should be updated. However, if important new evidence is published prior to the 5-year cycle, the review process may be accelerated for a more rapid update of some recommendations.
Sponsors: This guideline was developed with resources funded by the Society of Gynecologic Oncology of Canada and SOGC.
Summary statements: RECOMMENDATIONS.
Keywords: Serous ovarian neoplasms; fallopian tube neoplasms; primary prevention; salpingectomy.
Copyright © 2017 The Society of Obstetricians and Gynaecologists of Canada/La Société des obstétriciens et gynécologues du Canada. Published by Elsevier Inc. All rights reserved.
Similar articles
-
Guideline No. 403: Initial Investigation and Management of Adnexal Masses.J Obstet Gynaecol Can. 2020 Aug;42(8):1021-1029.e3. doi: 10.1016/j.jogc.2019.08.044. J Obstet Gynaecol Can. 2020. PMID: 32736853 Review.
-
No. 370-Management of Squamous Cell Cancer of the Vulva.J Obstet Gynaecol Can. 2019 Jan;41(1):89-101. doi: 10.1016/j.jogc.2018.07.004. J Obstet Gynaecol Can. 2019. PMID: 30580832
-
No. 385-Indications for Pelvic Examination.J Obstet Gynaecol Can. 2019 Aug;41(8):1221-1234. doi: 10.1016/j.jogc.2018.12.007. J Obstet Gynaecol Can. 2019. PMID: 31331610
-
Guideline No. 390-Classification and Management of Endometrial Hyperplasia.J Obstet Gynaecol Can. 2019 Dec;41(12):1789-1800. doi: 10.1016/j.jogc.2019.03.025. J Obstet Gynaecol Can. 2019. PMID: 31785798
-
Guideline No. 408: Management of Gestational Trophoblastic Diseases.J Obstet Gynaecol Can. 2021 Jan;43(1):91-105.e1. doi: 10.1016/j.jogc.2020.03.001. J Obstet Gynaecol Can. 2021. PMID: 33384141 Review.
Cited by
-
Functional Morphology of the Human Uterine Tubes in the 21st Century: Anatomical Novelties and Their Possible Clinical Applications.Physiol Res. 2022 Dec 27;71(Suppl 1):S151-S159. doi: 10.33549/physiolres.935036. Physiol Res. 2022. PMID: 36592451 Free PMC article.
-
Opportunistic salpingectomy at benign gynecological surgery for reducing ovarian cancer risk: a 10-year single centre experience from China and a literature review.J Cancer. 2018 Jan 1;9(1):141-147. doi: 10.7150/jca.21187. eCollection 2018. J Cancer. 2018. PMID: 29290779 Free PMC article.
-
The rationale of opportunistic bilateral salpingectomies (OBS) during benign gynaecological and obstetric surgery: a consensus text of the Flemish Society of Obstetrics and Gynaecology (VVOG).Facts Views Vis Obgyn. 2019 Jun;11(2):177-187. Facts Views Vis Obgyn. 2019. PMID: 31824638 Free PMC article.
-
Effect of salpingectomy versus tubal ligation on postoperative wound infection in patients: A meta-analysis.Int Wound J. 2024 Jan;21(1):e14543. doi: 10.1111/iwj.14543. Int Wound J. 2024. Retraction in: Int Wound J. 2025 Apr;22(4):e70614. doi: 10.1111/iwj.70614. PMID: 38272821 Free PMC article. Retracted.
-
Implementation of opportunistic salpingectomy for ovarian cancer prevention: Analyzing clinical practice and key characteristics.Acta Obstet Gynecol Scand. 2025 Aug;104(8):1539-1549. doi: 10.1111/aogs.15128. Epub 2025 Jun 5. Acta Obstet Gynecol Scand. 2025. PMID: 40470705 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical